EP238/#618 High FKBPL expression contributes to cell proliferation by regulating the cell cycle and affects prognosis in ovarian cancer patients. (4th December 2022)

• Record Type: Journal Article
• Authors: Kim, Hyosun; Han, Gwan Hee; Yun, Hee; Kim, Jae-Hoon; Cho, Hanbyoul
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A146
• Page End: A146
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.329
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: About 70% of ovarian cancer patients experience recurrence, and resistance is induced by repeated chemotherapy. So, research for novel therapeutic approach is urgently needed. FK506-binding protein like (FKBPL) is involved in immune & inflammatory responses, and signaling pathways regulating various cancers. However, the role of FKBPL in epithelial ovarian cancer (EOC) has not been elucidated. Methods: Immunohistochemical analysis of FKBPL expression using tissue microarray was performed on 398 epithelial ovarian tissues (186 cancer, 49 borderline, 84 benign, and 79 normal tissues). The clinico-pathological parameters and those data were compared. It was also performed in vitro to investigate the functional role of FKBPL in ovarian cancer cell lines. Results: The expression of FKBPL in ovarian cancer tissue was upregulated than other epithelial tissues (all p < 0.001). Importantly, FKBPL expression was associated with stage, tumor grade, cell type, and chemotherapy response (p ≤ 0.05). Multivariate survival analysis showed that overexpression of FKBPL was associated with poor overall survival (HR = 3.58; 95% CI: 1.87–6.84, p < 0.001) and disease-free survival (HR = 3.1; 95% CI: 1.97–4.87, p < 0.001). In-vitro results also showed that knockdown of FKBPL was associated with decreased cell proliferation, inhibited colony formation, and induction of G1 phase cell cycle arrest, supporting an oncogenic role of FKBPL in ovarian cancer cell lines. Conclusions: Overexpression of FKBPL could be a significant biomarker for predicting poor survival after chemotherapy. In addition, future research that reveals the mechanism of FKBPL on the cancer cell cycle will lead to the development of new anticancer drugs.